Clinical Trials Directory

Trials / Completed

CompletedNCT02463357

Three New Ideas to Protect Special Forces From the Stress of High Altitude

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
148 (actual)
Sponsor
University of Colorado, Denver · Academic / Other
Sex
Male
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance and endurance exercise capacity are impaired. Therefore, the goal of this research is to identify effective pharmacological agents that will help reduce the symptoms of AMS and improve physical and cognitive performance at high altitude. The investigators will study the efficacy of the dietary supplement, quercetin, the drugs nifedipine (extended release) and methazolamide taken together, the drug metformin, and the drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTQuercetin
DRUGNifedipine extended release
DRUGMethazolamide
DRUGMetformin
DRUGPlacebo
DRUGNitrite

Timeline

Start date
2015-08-01
Primary completion
2016-09-01
Completion
2016-09-01
First posted
2015-06-04
Last updated
2021-03-30
Results posted
2021-03-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02463357. Inclusion in this directory is not an endorsement.